In this episode of PWS United, we explore the science and hope behind Aardvark Therapeutics’ ARD-101, an investigational treatment currently in its Phase 3 clinical trial for Prader-Willi syndrome. Our guests, Dr. Tien Lee, CEO of Aardvark Therapeutics, and Dr. Manasi Jaiman, Chief Medical Officer, break down the difference between hunger and appetite, and how ARD-101 targets gut-brain signaling to reduce hyperphagia.

Dr. Lee and Dr. Jaiman also share insights into Aardvark’s uniquely compassionate approach to clinical trials, including their close engagement with the PWS community. Tune in to learn how this innovative therapy could impact the future of care for individuals living with PWS.

We’re proud to recognize Aardvark Therapeutics as our Diamond Sponsor for the 2025 International PWS Conference – United in Hope, happening this June in Phoenix, Arizona. Visit their exhibitor table and meet many members of their team in person!

Important Links:

• Learn more about Aardvark Therapeutics: https://aardvarktherapeutics.com
• Learn more about the ARD-101 Phase 3 clinical trial: https://clinicaltrials.gov/study/NCT06828861?intr=ARD-101&rank=4
• PWSA | USA: https://www.pwsausa.org
• Contact us: [email protected]
• 2025 International PWS Conference: https://pwsausaevents.cventevents.com/event/04353c7a-d6b1-45f9-9d6f-48acda9cd07e/home

Intro Music: https://www.bensound.com/; License certificate #2242442